(Q43880475)

27 November 2017

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant (English)

1 reference

27 November 2017

7

Barbara Ensoli

1 reference

27 November 2017

Stefan Borsutzky

1

1 reference

27 November 2017

Thomas Ebensen

2

1 reference

27 November 2017

Claudia Link

3

1 reference

27 November 2017

Pablo Daniel Becker

4

1 reference

27 November 2017

Valeria Fiorelli

5

1 reference

27 November 2017

Aurelio Cafaro

6

1 reference

27 November 2017

Carlos A Guzmán

8

1 reference

27 November 2017

language of work or name

English

0 references

publication date

28 November 2005

1 reference

27 November 2017

1 reference

27 November 2017

24

1 reference

27 November 2017

2049-2056

1 reference

27 November 2017

12

1 reference

The basis for HIV immunotherapeutic vaccines

27 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

HIV-1 prophylactic vaccine trials in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

The trans-activator gene of HTLV-III is essential for virus replication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Novel biocompatible anionic polymeric microspheres for the delivery of the HIV-1 Tat protein for vaccine application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Recent advances in the development of HIV-1 Tat-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

HIV-1 Tat-based vaccines: from basic science to clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Tat-mediated protein delivery can facilitate MHC class I presentation of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Efficient mucosal delivery of the HIV-1 Tat protein using the synthetic lipopeptide MALP-2 as adjuvant.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Isolation, structure elucidation, and synthesis of a macrophage stimulatory lipopeptide from Mycoplasma fermentans acting at picomolar concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Identification of a peptide capable of inducing an HIV-1 Tat-specific CTL response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

The role of helper T cell products in mouse B cell differentiation and isotype regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

TGF-beta receptor signaling is critical for mucosal IgA responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Regulation of immune responses by TGF-beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Skewed maturation of memory HIV-specific CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Medicine. The need for a global HIV vaccine enterprise

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Cytotoxic T-lymphocyte (CTL) responses directed against regulatory and accessory proteins in HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

Differences in expression of toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

BALB/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL/6 mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.11.025

10.1016/J.VACCINE.2005.11.025

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference